Clinical Study to Assess Safety, PK and PD Parameters of CDR132L
Status:
Completed
Trial end date:
2020-06-26
Target enrollment:
Participant gender:
Summary
This is a Phase I, randomized, double-blind, placebo-controlled study to assess safety,
pharmacokinetics and pharmacodynamic parameters of CDR132L in patients with stable heart
failure of ischemic origin (NYHA 1-3).